ADAP

Adaptimmune Therapeutics plc

1.61 USD
+0.02 (+1.26%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adaptimmune Therapeutics plc stock is up 61% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 March’s closed higher than February.

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)